Fluxion Biosciences To Distribute Millipore PrecisION® Ion Channel Cell Lines

Combination with IonFlux™ Automated Patch Clamp System creates a validated, affordable solution for ion channel profiling and screening

document.addEventListener("googletagEvent", function() { googletag.cmd.push(function() { googletag.display('ad-slot_1__mobile'); }); });

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Fluxion Biosciences today announced that it has signed a distribution agreement for EMD Millipore’s PrecisION® range of ion channel cell lines. The non-exclusive distribution agreement will combine Fluxion’s IonFlux automated patch clamp instrumentation with EMD Millipore’s broad suite of ion channel cell lines. Through the agreement, Fluxion will provide IonFlux customers with cell lines that have been performance validated on the IonFlux automated patch clamp platform, eliminating the risk and delays associated with the assay optimization process.

The IonFlux system tests ion channels by automating the traditional “patch clamp” technique, which allows the promising yet challenging ion channel drug target class to be screened in a physiologically relevant context. Ideal for a range of ion channel screening applications requiring 10 to 10,000 or more assays per day, the IonFlux automated patch clamp system combines flexibility and simplicity with time and cost savings. The recent introduction of the single cell giga-seal consumable completes the system capabilities that include high success rate cell ensemble recording and continuous perfusion. The IonFlux system provides an extremely compact plate reader format, making it ideal for users from individual researchers to high throughput screening centers. A broad range of global biopharmaceutical companies and leading academic institutions has adopted the IonFlux system, including Pfizer, Novartis, Genentech, Sanofi-Aventis, Cornell, University of Melbourne, University of Michigan, and University of Wisconsin.

“Our goal in the development of the IonFlux system was to provide not only the highest performance automated patch clamp system on the market, but also to make it the most affordable and easiest to use,” noted Jeff Jensen, Fluxion’s CEO. “We exceeded our goals and have now placed IonFlux systems in numerous screening labs, but also in many laboratories that lacked either the expertise or the budget for a typical automated patch clamp system. Successful electrophysiology assays are critically dependent on working with the right cell line and tailored recording protocols. Fluxion has removed this hurdle by developing optimized assays, including buffer formulations, cell preparation instructions, and protocols, that utilize commercially available cell lines. Validating and distributing EMD Millipore’s industry-leading PrecisION cell lines in combination with our IonFlux systems allows us to provide a complete, fully validated ion channel assay solution.”

EMD Millipore’s renowned PrecisION® Ion Channel cell lines are the industry standard for electrophysiology screening and profiling. PrecisION® cell lines offer the broadest range of ion channel cell lines validated for use on automated patch clamp and conventional patch rigs. A wide range of cell lines is available for cell culture or as cryo-preserved Ready-to-Assay™ cells. “Our goal is to provide validated cell lines that deliver the highest performance across the broadest range of applications,” stated Umesh Patel, Director, Lead Discovery at EMD Millipore. “Providing cells through Fluxion that have been fully validated on their IonFlux system is a natural extension of these goals, and it provides our customers with a complete, one-stop solution for their electrophysiology screening and profiling needs.”

The availability of PrecisION® cell lines through Fluxion is effective immediately. A broad range of IonFlux-validated cell lines is available, including hERG, GABA, and sodium channels.

document.addEventListener("googletagEvent", function() { googletag.cmd.push(function() { googletag.display('ad-slot_2__mobile'); }); });

About Fluxion Biosciences

Fluxion Biosciences provides cellular analysis tools for use in critical life science research and drug discovery applications. Fluxion’s proprietary microfluidic platform automates complex cell analysis workflows. Products include the BioFlux™ system for studying cellular interactions, the IonFlux™ system for automated ion channel testing, and the IsoFlux system for circulating tumor cell analysis. Fluxion’s systems meet the rigorous demands of life science and drug discovery scientists by providing an intuitive, easy-to-use operating system for single-cell biology. For more information about Fluxion Biosciences, visit www.fluxionbio.com.

About EMD Millipore

EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.

Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 67 countries and 2010 revenues of $2.2 billion. EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.

Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany



CONTACT:

Fluxion Biosciences
Mike Schwartz, 650-241-4737
mike.schwartz@fluxionbio.com

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Pharmaceutical  Research  Science

MEDIA:

Logo Image removed.
Read more on